Metastatic Nasopharyngeal Cancer Clinical Trial
Official title:
A Phase II Study: Safety and Efficacy of Combining Radiation Therapy With Immunotherapy and Chemotherapy in de Novo Metastatic Nasopharyngeal Carcinoma
Incidences of de novo metastatic nasopharyngeal carcinoma range from 6% to 8% at the time of presentation. For the initial diagnosis of metastatic NPC, PD-1 plus chemotherapy yields a satisfactory outcome with1year PFS of 40%. Previous study demonstrated the benefit of adding radiotherapy to chemotherapy in metastatic NPC, however there is no evidence whether radiotherapy can further improve PFS based on chemotherapy plus PD-1 . The purpose of this study is to evaluate the safety and effectiveness of first-line immunochemotherapy combined with radiotherapy for initial diagnosed metastatic NPC.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05198479 -
Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in
|
Phase 2 | |
| Not yet recruiting |
NCT03813394 -
Bevacizumab and Pembrolizumab Combination in EBER-ISH Positive NPC
|
Phase 1/Phase 2 | |
| Completed |
NCT03007836 -
High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer
|
Phase 1/Phase 2 |